Global Breast Cancer Treatment Market was Valued at US$ XX Mn in 2018, Rising Prevalence of Cancer Rates.
Analyst Speak:

“The Global Breast Cancer Treatment Market was valued around US$ XX Mn by 2018 and growing at a significant CAGR of XX% over next seven years 2019-2025 owing to rising prevalence of cancer rates”

The global breast cancer treatment market accounted for US$ XX Mn in 2018 and burgeoning over the forthcoming years. Some of the key factors boosting the market growth are rising prevalence of cancer rates, technological advancements in cancer biology coupled with introduction of various diagnostic & screening programs, easy availability of treatment of cancer and supportive government initiatives & improvement in the healthcare facilities. However, lack of awareness and huge cost involved in drug development are hampering the growth of the market.

Global breast cancer treatment market segmented on the basis of drug class, distribution channel and region.


Request Sample Report:
https://www.precisionbusinessinsights.com/request-sample?product_id=15801


Taxanes Dominate the Global Breast Cancer Treatment Market

Based on drug class, global breast cancer treatment market segmented into taxanes, hormonal therapy, epothilones, aromatase inhibitors, antimetabolites, anthracyclines, alkylating agents and selective oestrogen-receptor modulators. Taxanes segment held considerable market growth during estimated period. It is a type of drug that blocks cell growth by stopping mitosis (cell division). Taxanes interfere with microtubules (cellular structures that help move chromosomes during mitosis). They are used to treat cancer. A taxane is a type of mitotic inhibitor and a type of antimicrotubule agent. The introduction of taxanes marked a significant advance in the treatment of MBC (metastatic breast cancer). According to the clinical trials, these potent antitumor agents provide improved outcomes for patients with both early and advanced disease and these are among the most active chemotherapy agents used in the management of metastatic breast cancer.

North America Leads the Global Breast Cancer Treatment market

PBI’s global breast cancer treatment market report analyses the market in different regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. According to regional analysis. This region is one of the key markets for Breast Cancer Treatment. The region has witnessed considerable growth in this market owing to the rising prevalence of breast cancer, new drug approvals which are considered to be the primary reasons for the high growth of the market in this region. Asia Pacific is witnessing considerable growth in this market due to rise in patient pool with breast cancer disease, advancements in healthcare facilities and increasing government initiatives favouring the market growth in this particular region.

Strategic New Product Launches are the Key Strategies Adopted by Market Players

Global breast cancer treatment market further reveals that the key players increasingly adopting strategies such as launch of newer products, frequent product approvals, and long term alliance to improve market revenue share and gaining significant geographic presence across the region. For Instance, in 2019, Emcure Pharma launched the generic version of Eisai Pharma’s breast cancer medicine Eribulin, which would be 40% cheaper than the innovator’s. Eribulin, sold by Japanese drug maker Eisai under brand name Halaven, is used to treat HER 2 negative patients.


Key player’s profiles in the report are Bayer AG (Germany), Novartis AG (Switzerland), GlaxoSmithKline plc (U.K.), Eli Lilly and Company (U.S.), Hoffmann-La Roche Ltd (Switzerland), Actavis, Inc. (U.S.), AstraZeneca (U.K.), Bristol-Myers Squibb Company (U.S.), Pfizer, Inc (U.S.) and Sanofi (France).

Precision Business Insights (PBI) in its report titled “Global Breast Cancer Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2014-2018 and Forecast 2019-2025” assesses the market performance over seven years forecast period over 2019-2025. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period. Moreover, the report also includes the total revenue and volume for the market.

Detailed Segmentation

By Drug Class
o Taxanes
o Hormonal therapy
o Epothilones
o Aromatase inhibitors
o Antimetabolites
o Anthracyclines
o Alkylating agents
o Selective Oestrogen-receptor modulators

By Distribution Channel
o Retail Pharmacies
o Hospital Pharmacies
o Online Pharmacies

By Geography
o North America
• US
• Canada
o Europe
• Germany
• France
• UK
• Italy
• Spain
• Russia
• Poland
• Rest of Europe
o Asia-Pacific
• Japan
• China
• India
• Australia & New Zealand
• ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
• South Korea
• Rest of Asia-Pacific
o Latin America
• Brazil
• Mexico
• Argentina
• Rest of Latin America
o Middle East and Africa (MEA)
• Gulf Cooperation Council (GCC) Countries
• Israel
• South Africa
• Rest of MEA


For More Information:
https://www.precisionbusinessinsights.com/market-reports/global-breast-cancer-treatment-market/


About:
Precision Business Insights is one of the leading market research and management consulting firm, run by a group of seasoned and highly dynamic market research professionals with a strong zeal to offer high-quality insights.

Contact Us:

Shreya Paul
Senior Business Development Executive
Email @ [email protected]
Call @ +1-866-598-1553
Precision Business Insights Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com